{"id":"maximum-androgen-blockade","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"70-90","effect":"Erectile dysfunction"},{"rate":"10-20","effect":"Gynecomastia"},{"rate":"30-50","effect":"Fatigue"},{"rate":"60-80","effect":"Decreased libido"},{"rate":"20-40","effect":"Weight gain"},{"rate":"variable with duration","effect":"Osteoporosis/bone loss"}]},"_chembl":{"chemblId":"CHEMBL1200527","moleculeType":"Small molecule","molecularWeight":"1243.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic strategy uses a combination approach: an antiandrogen (such as bicalutamide or flutamide) blocks androgen receptors on cancer cells, while a gonadotropin-releasing hormone (GnRH) agonist or 5-alpha reductase inhibitor suppresses testosterone production. Together, these agents eliminate both circulating androgens and local androgen signaling, maximizing suppression of androgen-dependent prostate cancer growth.","oneSentence":"Maximum androgen blockade combines androgen receptor antagonists with androgen synthesis inhibitors to suppress testosterone production and block its effects in prostate cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:02.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic prostate cancer"},{"name":"Locally advanced prostate cancer"},{"name":"High-risk localized prostate cancer (in combination with radiation therapy)"}]},"trialDetails":[{"nctId":"NCT04360941","phase":"PHASE1","title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2020-08-11","conditions":"Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer","enrollment":45},{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Prostate Cancer","enrollment":1600},{"nctId":"NCT03869762","phase":"PHASE2","title":"Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-01-09","conditions":"Castration-resistant Prostate Cancer, Metastatic Cancer, Bone Metastases","enrollment":7},{"nctId":"NCT03575819","phase":"PHASE1","title":"A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"COMPLETED","sponsor":"Fortis Therapeutics, Inc.","startDate":"2019-02-04","conditions":"Prostate Cancer Metastatic","enrollment":56},{"nctId":"NCT04248621","phase":"PHASE4","title":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2020-01-23","conditions":"Prostatic Neoplasms","enrollment":164},{"nctId":"NCT03587285","phase":"PHASE1, PHASE2","title":"A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer","status":"UNKNOWN","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2018-09-23","conditions":"Prostatic Neoplasms","enrollment":11},{"nctId":"NCT03701659","phase":"NA","title":"TUPKRP Combined With MAB Therapy for LUTS/PCa","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2018-12-01","conditions":"Advanced Prostate Cancer, Lower Urinary Tract Symptoms, Quality of Life","enrollment":100},{"nctId":"NCT02424448","phase":"","title":"Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2014-12","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":6},{"nctId":"NCT00685646","phase":"PHASE3","title":"Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-05","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":227},{"nctId":"NCT01839994","phase":"PHASE3","title":"Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2013-06","conditions":"Prostate Cancer","enrollment":350},{"nctId":"NCT00554086","phase":"PHASE2","title":"Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.","status":"COMPLETED","sponsor":"Canadian Urology Research Consortium","startDate":"2005-11","conditions":"Prostate Cancer","enrollment":65},{"nctId":"NCT00255268","phase":"PHASE4","title":"CMAB vs IMAB in Metastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Metastatic Prostate Cancer","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LHRN agonist and antiandrogen"],"phase":"marketed","status":"active","brandName":"Maximum androgen blockade","genericName":"Maximum androgen blockade","companyName":"Wonju Severance Christian Hospital","companyId":"wonju-severance-christian-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Maximum androgen blockade combines an androgen receptor antagonist with an androgen synthesis inhibitor to suppress testosterone production and block its effects in prostate cancer cells. Used for Metastatic prostate cancer, Advanced prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}